Evofem Biosciences, Inc.

For the period ended Dec 31, 2025. Filed Mar 11, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 11, 2026

EVFM$0.48-23.4%Stored close · as of Aug 10, 2022

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations

(In thousands, except share and per share data)

	Years Ended December 31,
	2025	2024
Product sales, net	$20,183	$19,363
Operating Expenses:
Cost of goods sold	4,617	3,834
Gain on change in accounting estimates on contingent royalty liability (Note 7)	(1,933)	-
Amortization of intangible asset	499	619
Research and development, net	(3,447)	1,845
Selling and marketing	9,682	9,176
General and administrative	7,393	11,565
Total operating expenses	16,811	27,039
Income (loss) from operations	3,372	(7,676)
Other income (expense):
Interest income	15	16
Other expense, net	(2,635)	(2,575)
Loss on issuance of financial instruments	-	(3,300)
Gain on debt extinguishment, net	-	977
Change in fair value of financial instruments	(359)	3,698
Total other expense, net	(2,979)	(1,184)
Income (loss) before income tax expense	393	(8,860)
Income tax expense	(2)	-
Net income (loss)	391	(8,860)
Convertible preferred stock deemed dividends	(117)	(105)
Net income (loss) attributable to common stockholders	$274	$(8,965)
Net income (loss) per share attributable to common stockholders:
Basic (Note 2)	$0.00	$(0.11)
Diluted (Note 2)	$0.00	$(0.11)
Weighted-average shares used to compute net income (loss) per share attributable to common stockholders:
Basic	123,657,915	80,003,309
Diluted	6,421,746,555	80,003,309

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.